Showing results (251-260 of 498) with videos related to

Sort By:
Pageof 50
Blood Research|August 15, 2025
Hepatitis B virus reactivation in patients with hematologic malignancies treated with Bruton tyrosine kinase inhibitorsJoon Young Hur, Jung-Hee Lee, Je-Hwan Lee, et al.
The Korean Journal of Hematology|April 6, 2012
A phase I/II study of bortezomib plus CHOP every 2 weeks (CHOP-14) in patients with advanced-stage diffuse large B-cell lymphomasJeong Eun Kim, Dok Hyun Yoon, Geundoo Jang, et al.
Anticancer Research|April 12, 2015
The clinical significance of activated p-AKT expression in peripheral T-cell lymphomaJung Yong Hong, Min Eui Hong, Moon Ki Choi, et al.
Urologic Oncology|November 4, 2008
Molecular biomarkers for advanced renal cell carcinoma: implications for prognosis and therapyHyo Song Kim, Won Seog Kim, Se Hoon Park, et al.
Cancer Chemotherapy and Pharmacology|March 18, 2016
Results of a phase II study of vorinostat in combination with intravenous fludarabine, mitoxantrone, and dexamethasone in patients with relapsed or refractory mantle cell lymphoma: an interim analysisDong-Yeop Shin, Seok Jin Kim, Dok Hyun Yoon, et al.
Cancer Research and Treatment|March 3, 2022
Circulating Tumor DNA-Based Genotyping and Monitoring for Predicting Disease Relapses of Patients with Peripheral T-Cell LymphomasSeok Jin Kim, Yeon Jeong Kim, Sang Eun Yoon, et al.
International Forum of Allergy & Rhinology|June 4, 2015
Nasal endoscopic evaluation and its impact on survival in patients with stage I/II extranodal natural killer/T-cell lymphoma, nasal typeHyun-Jin Cho, Min-Seok Jang, Sang Duk Hong, et al.
Oncology|May 25, 2011
Analysis of prognostic factors of pediatric-type sarcomas in adult patientsHee Kyung Ahn, Ji Eun Uhm, Jeeyun Lee, et al.
Investigational New Drugs|May 8, 2009
Phase II study of gemcitabine for treatment of patients with advanced stage marginal zone B-cell lymphoma: Consortium for Improving Survival of Lymphoma (CISL) trialSung Yong Oh, Won Seog Kim, Dae Ho Lee, et al.
Blood Advances|June 21, 2021
Zanubrutinib for the treatment of relapsed or refractory mantle cell lymphomaConstantine S Tam, Stephen Opat, David Simpson, et al.
Pageof 50